Journal
CURRENT ATHEROSCLEROSIS REPORTS
Volume 13, Issue 3, Pages 249-256Publisher
CURRENT MEDICINE GROUP
DOI: 10.1007/s11883-011-0171-6
Keywords
Lecithin cholesterol acyltransferase; High-density lipoprotein; Fish-eye disease; Cholesterol; Reverse cholesterol transport; Atherosclerosis; Enzyme replacement therapy; Biomarker
Categories
Funding
- National Institutes of Health
Ask authors/readers for more resources
Lecithin cholesterol acyl transferase (LCAT) is a plasma enzyme that esterifies cholesterol and raises high-density lipoprotein cholesterol, but its role in atherosclerosis is not clearly established. Studies of various animal models have yielded conflicting results, but studies done in rabbits and non-human primates, which more closely simulate human lipoprotein metabolism, indicate that LCAT is likely atheroprotective. Although suggestive, there are also no biomarker studies that mechanistically link LCAT with cardiovascular disease. Imaging studies of patients with LCAT deficiency have also not yielded a clear answer to the role of LCAT in atherosclerosis. Recombinant LCAT, however, is currently being developed as a therapeutic product for enzyme replacement therapy of patients with genetic disorders of LCAT for the prevention and/or treatment of renal disease, but it may also have value for the treatment of acute coronary syndrome.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available